TY - JOUR PY - 2012 DA - 2012// TI - Comprehensive molecular portraits of human breast tumours JO - Nature VL - 490 UR - https://doi.org/10.1038/nature11412 DO - 10.1038/nature11412 ID - ref1 ER - TY - JOUR AU - Holbro, T. AU - Beerli, R. R. AU - Maurer, F. AU - Koziczak, M. AU - Barbas, C. F. AU - Hynes, N. E. PY - 2003 DA - 2003// TI - The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation JO - Proc Natl Acad Sci U S A VL - 100 UR - https://doi.org/10.1073/pnas.1537685100 DO - 10.1073/pnas.1537685100 ID - Holbro2003 ER - TY - JOUR AU - Utermark, T. AU - Rao, T. AU - Cheng, H. AU - Wang, Q. AU - Lee, S. H. AU - Wang, Z. C. PY - 2012 DA - 2012// TI - The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis JO - Genes Dev VL - 26 UR - https://doi.org/10.1101/gad.191973.112 DO - 10.1101/gad.191973.112 ID - Utermark2012 ER - TY - JOUR AU - Vaught, D. B. AU - Stanford, J. C. AU - Young, C. AU - Hicks, D. J. AU - Wheeler, F. AU - Rinehart, C. PY - 2012 DA - 2012// TI - HER3 Is Required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3594 DO - 10.1158/0008-5472.CAN-11-3594 ID - Vaught2012 ER - TY - JOUR AU - Maroulakou, I. G. AU - Oemler, W. AU - Naber, S. P. AU - Tsichlis, P. N. PY - 2007 DA - 2007// TI - Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-3782 DO - 10.1158/0008-5472.CAN-06-3782 ID - Maroulakou2007 ER - TY - JOUR AU - Ju, X. AU - Katiyar, S. AU - Wang, C. AU - Liu, M. AU - Jiao, X. AU - Li, S. PY - 2007 DA - 2007// TI - Akt1 governs breast cancer progression in vivo JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0605874104 DO - 10.1073/pnas.0605874104 ID - Ju2007 ER - TY - JOUR AU - Jia, S. AU - Liu, Z. AU - Zhang, S. AU - Liu, P. AU - Zhang, L. AU - Lee, S. H. PY - 2008 DA - 2008// TI - Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis JO - Nature VL - 454 ID - Jia2008 ER - TY - JOUR AU - Arteaga, C. L. AU - Sliwkowski, M. X. AU - Osborne, C. K. AU - Perez, E. A. AU - Puglisi, F. AU - Gianni, L. PY - 2012 DA - 2012// TI - Treatment of HER2-positive breast cancer: current status and future perspectives JO - Nat Rev Clin Oncol VL - 9 UR - https://doi.org/10.1038/nrclinonc.2011.177 DO - 10.1038/nrclinonc.2011.177 ID - Arteaga2012 ER - TY - STD TI - Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Breast Cancer Special Feature: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012;109(8):2718-23. ID - ref9 ER - TY - JOUR AU - Garrett, J. T. AU - Olivares, M. G. AU - Rinehart, C. AU - Granja-Ingram, N. D. AU - Sanchez, V. AU - Chakrabarty, A. PY - 2011 DA - 2011// TI - Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1016140108 DO - 10.1073/pnas.1016140108 ID - Garrett2011 ER - TY - JOUR AU - Junttila, T. T. AU - Akita, R. W. AU - Parsons, K. AU - Fields, C. AU - Lewis Phillips, G. D. AU - Friedman, L. S. PY - 2009 DA - 2009// TI - Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 JO - Cancer Cell VL - 15 UR - https://doi.org/10.1016/j.ccr.2009.03.020 DO - 10.1016/j.ccr.2009.03.020 ID - Junttila2009 ER - TY - JOUR AU - Rexer, B. N. AU - Chanthaphaychith, S. AU - Dahlman, K. AU - Arteaga, C. L. PY - 2014 DA - 2014// TI - Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells JO - Breast Cancer Res VL - 16 UR - https://doi.org/10.1186/bcr3601 DO - 10.1186/bcr3601 ID - Rexer2014 ER - TY - JOUR AU - Serra, V. AU - Scaltriti, M. AU - Prudkin, L. AU - Eichhorn, P. J. AU - Ibrahim, Y. H. AU - Chandarlapaty, S. PY - 2011 DA - 2011// TI - PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer JO - Oncogene VL - 30 UR - https://doi.org/10.1038/onc.2010.626 DO - 10.1038/onc.2010.626 ID - Serra2011 ER - TY - JOUR AU - Laplante, M. AU - Sabatini, D. M. PY - 2012 DA - 2012// TI - mTOR signaling in growth control and disease JO - Cell VL - 149 UR - https://doi.org/10.1016/j.cell.2012.03.017 DO - 10.1016/j.cell.2012.03.017 ID - Laplante2012 ER - TY - JOUR AU - Russell, R. C. AU - Yuan, H. X. AU - Guan, K. L. PY - 2014 DA - 2014// TI - Autophagy regulation by nutrient signaling JO - Cell Res VL - 24 UR - https://doi.org/10.1038/cr.2013.166 DO - 10.1038/cr.2013.166 ID - Russell2014 ER - TY - JOUR AU - Kim, J. AU - Kundu, M. AU - Viollet, B. AU - Guan, K. L. PY - 2011 DA - 2011// TI - AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 JO - Nat Cell Biol VL - 13 UR - https://doi.org/10.1038/ncb2152 DO - 10.1038/ncb2152 ID - Kim2011 ER - TY - JOUR AU - Russell, R. C. AU - Tian, Y. AU - Yuan, H. AU - Park, H. W. AU - Chang, Y. Y. AU - Kim, J. PY - 2013 DA - 2013// TI - ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase JO - Nat Cell Biol VL - 15 UR - https://doi.org/10.1038/ncb2757 DO - 10.1038/ncb2757 ID - Russell2013 ER - TY - JOUR AU - Kim, J. AU - Kim, Y. C. AU - Fang, C. AU - Russell, R. C. AU - Kim, J. H. AU - Fan, W. PY - 2013 DA - 2013// TI - Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy JO - Cell VL - 152 UR - https://doi.org/10.1016/j.cell.2012.12.016 DO - 10.1016/j.cell.2012.12.016 ID - Kim2013 ER - TY - JOUR AU - Fan, Q. W. AU - Cheng, C. AU - Hackett, C. AU - Feldman, M. AU - Houseman, B. T. AU - Nicolaides, T. PY - 2010 DA - 2010// TI - Akt and autophagy cooperate to promote survival of drug-resistant glioma JO - Sci Signal VL - 3 UR - https://doi.org/10.1126/scisignal.2001017 DO - 10.1126/scisignal.2001017 ID - Fan2010 ER - TY - JOUR AU - Fan, Q. W. AU - Weiss, W. A. PY - 2011 DA - 2011// TI - Autophagy and Akt promote survival in glioma JO - Autophagy VL - 7 UR - https://doi.org/10.4161/auto.7.5.14779 DO - 10.4161/auto.7.5.14779 ID - Fan2011 ER - TY - JOUR AU - Levy, J. M. AU - Thompson, J. C. AU - Griesinger, A. M. AU - Amani, V. AU - Donson, A. M. AU - Birks, D. K. PY - 2014 DA - 2014// TI - Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-14-0049 DO - 10.1158/2159-8290.CD-14-0049 ID - Levy2014 ER - TY - JOUR AU - Zhu, X. AU - Wu, L. AU - Qiao, H. AU - Han, T. AU - Chen, S. AU - Liu, X. PY - 2013 DA - 2013// TI - Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib JO - J Cell Biochem VL - 114 UR - https://doi.org/10.1002/jcb.24611 DO - 10.1002/jcb.24611 ID - Zhu2013 ER - TY - JOUR AU - Cufi, S. AU - Vazquez-Martin, A. AU - Oliveras-Ferraros, C. AU - Corominas-Faja, B. AU - Cuyas, E. AU - Lopez-Bonet, E. PY - 2013 DA - 2013// TI - The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer JO - Sci Rep VL - 3 ID - Cufi2013 ER - TY - JOUR AU - Stenvang, J. AU - Silahtaroglu, A. N. AU - Lindow, M. AU - Elmen, J. AU - Kauppinen, S. PY - 2008 DA - 2008// TI - The utility of LNA in microRNA-based cancer diagnostics and therapeutics JO - Semin Cancer Biol VL - 18 UR - https://doi.org/10.1016/j.semcancer.2008.01.004 DO - 10.1016/j.semcancer.2008.01.004 ID - Stenvang2008 ER - TY - JOUR AU - Zhang, Y. AU - Qu, Z. AU - Kim, S. AU - Shi, V. AU - Liao, B. AU - Kraft, P. PY - 2011 DA - 2011// TI - Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection JO - Gene Ther VL - 18 UR - https://doi.org/10.1038/gt.2010.133 DO - 10.1038/gt.2010.133 ID - Zhang2011 ER - TY - JOUR AU - Cook, R. S. AU - Garrett, J. T. AU - Sanchez, V. AU - Stanford, J. C. AU - Young, C. AU - Chakrabarty, A. PY - 2011 DA - 2011// TI - ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-3775 DO - 10.1158/0008-5472.CAN-10-3775 ID - Cook2011 ER - TY - JOUR AU - Wu, Y. AU - Zhang, Y. AU - Wang, M. AU - Li, Q. AU - Qu, Z. AU - Shi, V. PY - 2013 DA - 2013// TI - Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-12-0838 DO - 10.1158/1535-7163.MCT-12-0838 ID - Wu2013 ER - TY - JOUR AU - Xia, W. AU - Mullin, R. J. AU - Keith, B. R. AU - Liu, L. H. AU - Ma, H. AU - Rusnak, D. W. PY - 2002 DA - 2002// TI - Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways JO - Oncogene VL - 21 UR - https://doi.org/10.1038/sj.onc.1205794 DO - 10.1038/sj.onc.1205794 ID - Xia2002 ER - TY - STD TI - Voliva CF, Pecchi S, Burger M, Nagel T, Schnell C, Fritsch C, et al. Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials. In: 101st Annual Meeting of the American Association for Cancer Research: 2010 April 17–21 2010. Washington DC. 2010. ID - ref29 ER - TY - JOUR AU - Fritsch, C. AU - Huang, A. AU - Chatenay-Rivauday, C. AU - Schnell, C. AU - Reddy, A. AU - Liu, M. PY - 2014 DA - 2014// TI - Characterization of the Novel and Specific PI3Kalpha Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-13-0865 DO - 10.1158/1535-7163.MCT-13-0865 ID - Fritsch2014 ER - TY - JOUR AU - Jaber, N. AU - Dou, Z. AU - Chen, J. S. AU - Catanzaro, J. AU - Jiang, Y. P. AU - Ballou, L. M. PY - 2012 DA - 2012// TI - Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function JO - Proc Natl Acad Sci U S A VL - 109 UR - https://doi.org/10.1073/pnas.1112848109 DO - 10.1073/pnas.1112848109 ID - Jaber2012 ER - TY - JOUR AU - Ronan, B. AU - Flamand, O. AU - Vescovi, L. AU - Dureuil, C. AU - Durand, L. AU - Fassy, F. PY - 2014 DA - 2014// TI - A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy JO - Nat Chem Biol VL - 10 UR - https://doi.org/10.1038/nchembio.1681 DO - 10.1038/nchembio.1681 ID - Ronan2014 ER - TY - JOUR AU - Yao, E. AU - Zhou, W. AU - Lee-Hoeflich, S. T. AU - Truong, T. AU - Haverty, P. M. AU - Eastham-Anderson, J. PY - 2009 DA - 2009// TI - Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-2814 DO - 10.1158/1078-0432.CCR-08-2814 ID - Yao2009 ER - TY - JOUR AU - Hanker, A. B. AU - Pfefferle, A. D. AU - Balko, J. M. AU - Kuba, M. G. AU - Young, C. D. AU - Sanchez, V. PY - 2013 DA - 2013// TI - Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1303204110 DO - 10.1073/pnas.1303204110 ID - Hanker2013 ER - TY - JOUR AU - Garrett, J. T. AU - Sutton, C. R. AU - Kurupi, R. AU - Bialucha, C. U. AU - Ettenberg, S. A. AU - Collins, S. D. PY - 2013 DA - 2013// TI - Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110alpha inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-13-1191 DO - 10.1158/0008-5472.CAN-13-1191 ID - Garrett2013 ER - TY - JOUR AU - Jean, S. AU - Kiger, A. A. PY - 2014 DA - 2014// TI - Classes of phosphoinositide 3-kinases at a glance JO - J Cell Sci VL - 127 UR - https://doi.org/10.1242/jcs.093773 DO - 10.1242/jcs.093773 ID - Jean2014 ER - TY - JOUR AU - Bendell, J. C. AU - Rodon, J. AU - Burris, H. A. AU - Jonge, M. AU - Verweij, J. AU - Birle, D. PY - 2012 DA - 2012// TI - Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.1360 DO - 10.1200/JCO.2011.36.1360 ID - Bendell2012 ER - TY - JOUR AU - Hoshino, D. AU - Jourquin, J. AU - Emmons, S. W. AU - Miller, T. AU - Goldgof, M. AU - Costello, K. PY - 2012 DA - 2012// TI - Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCalpha invasive signaling axis JO - Sci Signal VL - 5 UR - https://doi.org/10.1126/scisignal.2002964 DO - 10.1126/scisignal.2002964 ID - Hoshino2012 ER - TY - JOUR AU - Courtney, K. D. AU - Corcoran, R. B. AU - Engelman, J. A. PY - 2010 DA - 2010// TI - The PI3K pathway as drug target in human cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.3641 DO - 10.1200/JCO.2009.25.3641 ID - Courtney2010 ER - TY - JOUR AU - Eichhorn, P. J. AU - Gili, M. AU - Scaltriti, M. AU - Serra, V. AU - Guzman, M. AU - Nijkamp, W. PY - 2008 DA - 2008// TI - Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1740 DO - 10.1158/0008-5472.CAN-08-1740 ID - Eichhorn2008 ER -